N(4)-Hydroxycytidine CAS 3258-02-4 EIDD-1931 NHC High Quality

Short Description:

Chemical Name: N(4)-Hydroxycytidine

Synonyms: EIDD-1931 (NHC); β-D-N4-Hydroxycytidine

CAS: 3258-02-4

Appearance: White to Off-White Powder Purity: ≥98.0%

An active metabolite of Molnupiravir (EIDD-2801), a promising COVID-19 inhibitor

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Product Detail

Related Products

Product Tags


Supply with High Purity and Stable Quality
Chemical Name: N(4)-Hydroxycytidine; EIDD-1931 (NHC) 
CAS: 3258-02-4 
An active metabolite of Molnupiravir, a promising COVID-19 inhibitor 

Chemical Properties:

Chemical Name N(4)-Hydroxycytidine
Synonyms EIDD-1931 (NHC); β-D-N4-Hydroxycytidine
CAS Number 3258-02-4
CAT Number RF-PI309
Stock Status In Stock, Production Scale Up to Kilograms
Molecular Formula C9H13N3O6
Molecular Weight 259.22
Melting Point 169.0~172.0℃
Solubility Soluble to 100 mM in DMSO and to 50 mM in Water
Density 1.93±0.1 g/cm3
Brand Ruifu Chemical


Item Specifications
Appearance White to Off-White Powder
NMR Consistent with Structure
Purity / Analysis Method >98% (HPLC)
Loss on Drying ≤1.0%
Single Impurity ≤0.50%
Heavy Metals ≤20ppm
Test Standard Enterprise Standard
Usage An active metabolite of Molnupiravir (EIDD-2801), a COVID-19 inhibitor

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.





N(4)-Hydroxycytidine (EIDD-1931 , β-d-N4-hydroxycytidine, NHC, CAS 3258-02-4) is an active metabolite of EIDD-2801, a promising COVID-19 inhibitor. EIDD-1931 (NHC) has broad spectrum antiviral activity against multiple coronaviruses, including SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs with average IC50 of 0.15 μM, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of Molnupiravir (EIDD-2801), an orally bioavailable NHC-prodrug (β-D-N4-hydroxycytidine-5'-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against multiple coronaviruses and oral bioavailability highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.

  • Write your message here and send it to us